Human medicines European public assessment report (EPAR): Upstaza, eladocagene exuparvovec, Date of authorisation: 18/07/2022, Revision: 9, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Spevigo, spesolimab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Congenital, familial and genetic disorders, PIP number: EMA/PE/0000232315

Committee for Medicinal Products for Veterinary Use (CVMP): 2-4 December 2025, European Medicines Agency, Amsterdam, the Netherlands, from 2 December 2025 to 4 December 2025

Agenda of the CVMP meeting 2-4 December 2025

Questions and answers on implementation of the medical devices and in vitro diagnostic medical devices Regulations ((EU) 2017/745 and (EU) 2017/746) - tracked changes

Questions and answers on implementation of the medical devices and in vitro diagnostic medical devices Regulations ((EU) 2017/745 and (EU) 2017/746)

IRIS guide for applicants - How to create, submit and manage IRIS applications, for industry and individual applicants

Union Product Database (UPD) - Questions & answers: Network use

Union Product Database (UPD) registration guide for UI and API users

Q&A clinic on Substance, Organisation, Referentials Management Services - January 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 January 2026, 11:00 (CET) to 13 January 2026, 12:00 (CET)